The U.S. Food and Drug Administration has approved expanded use of Vonvendi (von Willebrand factor [recombinant]) for routine prophylactic use in adults with all types of the blood-clotting disorder ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies, today announced interim clinical data from ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food & Drug Administration (FDA) approved VONVENDI® [von ...
PARAMUS, N.J., Dec. 5, 2023 /PRNewswire/ -- Octapharma USA announced the expansion of the U.S. Food and Drug Administration (FDA) approval for wilate ®, von Willebrand Factor/Coagulation Factor VIII ...
Star Therapeutics, a late clinical-stage biotechnology company focused on the discovery and development of life-changing therapies for diseases with significant unmet need, today announced an upcoming ...
Vonvendi is now approved for routine prophylaxis to reduce bleeding frequency in adults with all types of VWD (Type 1, 2, and 3). The Food and Drug Administration (FDA) has expanded the approval of ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies, today announced that the U.S. Food and Drug ...
PARAMUS, N.J. (Feb. 23, 2023) – Octapharma USA has submitted a Biologics License Application Supplement (sBLA) to the U.S. Food and Drug Administration (FDA) to expand the approval of wilate ®, von ...
Von Willebrand factor (VWF) is a protein crucial to the blood clotting process. If you don’t have enough of this protein, or if it doesn’t work as it’s supposed to, you may have von Willebrand disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results